Effects of eprosartan on glomerular injury in rats with reduced renal mass.
The effects of the selective angiotensin AT1 receptor antagonist, eprosartan, were evaluated in experimental renal disease. Five-sixth nephrectomy in male Munich-Wistar rats led to the development of hypertension, proteinuria and remnant glomerulosclerosis. Administration of the AT1 receptor antagonist, eprosartan, for 4 weeks resulted in inhibition of angiotensin II activity as confirmed by a reduced blood pressure response to exogenous angiotensin II challenge. Compared to vehicle treatment, eprosartan normalized blood pressure, reduced proteinuria and limited remnant glomerulosclerosis. These data suggest that eprosartan may provide a new tool in the treatment of progressive renal disease.
Gandhi
M
M
Department of Medicine, Palo Alto VA Health Care System and Stanford University, Palo Alto, Calif., USA.
Meyer
T W
TW
Brooks
D P
DP
D000179:Acrylates / Q000627:therapeutic use*; D000804:Angiotensin II / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D009392:Nephrectomy; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D013876:Thiophenes; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000179:Acrylates; D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D013876:Thiophenes; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; C068373:eprosartan